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Regulation of hepatic carbohydrate homeostasis is
crucial for maintaining energy balance in the face
of fluctuating nutrient availability. Here, we show
that the hormone fibroblast growth factor 15/19
(FGF15/19), which is released postprandially from
the small intestine, inhibits hepatic gluconeogenesis,
like insulin. However, unlike insulin, which peaks in
serum 15 min after feeding, FGF15/19 expression
peaks approximately 45 min later, when bile acid
concentrations increase in the small intestine.
FGF15/19 blocks the expression of genes involved
in gluconeogenesis through a mechanism involving
the dephosphorylation and inactivation of the tran-
scription factor cAMP regulatory element-binding
protein (CREB). This in turn blunts expression of
peroxisome proliferator-activated receptor g coacti-
vator-1a (PGC-1a) and other genes involved in
hepatic metabolism. Overexpression of PGC-1a
blocks the inhibitory effect of FGF15/19 on gluconeo-
genic gene expression. These results demonstrate
that FGF15/19 works subsequent to insulin as a
postprandial regulator of hepatic carbohydrate
homeostasis.
INTRODUCTION
Insulin and glucagon have well-established roles in controlling
substrate utilization and energy balance during the fed and
fasted states, respectively. More recently, human fibroblast
growth factor (FGF) 19 and its mouse ortholog, FGF15, were
identified as metabolic hormones (Fu et al., 2004; Inagaki
et al., 2005; Tomlinson et al., 2002). (We will refer to the hormone
as FGF15/19 unless specifically referring to the mouse FGF15 orChuman FGF19 orthologs.) FGF15/19 is an atypical FGF that lacks
the conventional heparin-binding domain found in most other
FGFs (Goetz et al., 2007). As a consequence, FGF15/19 circu-
lates as a hormone and signals through a cell-surface receptor
comprised of classical FGF receptors (FGFRs) complexed with
b-Klotho, a membrane-spanning protein (Kurosu et al., 2007;
Lin et al., 2007; Wu et al., 2007). FGF15/19 preferentially binds
and activates the FGFR4/b-Klotho complex.
FGF15/19 is a postprandial hormone whose expression is
induced in the small intestine by bile acids acting through
the nuclear bile acid receptor, FXR (Inagaki et al., 2005). In
humans, FGF19 plasma concentrations peak 2–3 hr after feeding
(Lunda˚sen et al., 2006; Walters et al., 2009). FGF15/19 circulates
to repress bile acid synthesis in liver and to promote gallbladder
filling (Choi et al., 2006; Holt et al., 2003; Inagaki et al., 2005;
Lunda˚sen et al., 2006). FGF15/19 also has broader effects on
energy homeostasis. Transgenic mice expressing FGF19 in
muscle have a higher basal metabolic rate and are resistant to
high-fat-diet-induced weight gain (Tomlinson et al., 2002). These
mice also have lower serum glucose and insulin levels and
enhanced insulin sensitivity. Administration of recombinant
FGF19 had similar metabolic effects in db/db and diet-induced
obese mice (Fu et al., 2004).
cAMP regulatory element-binding protein (CREB) is a tran-
scription factor that is activated by a diverse array of extracellular
signals (Goldman et al., 1997; Mayr and Montminy, 2001). In
liver, CREB regulates metabolism in response to fasting.
Glucagon and catecholamines activate CREB through protein
kinase A, which phosphorylates CREB at Ser133, thereby
promoting its interaction with transcriptional coactivator proteins
such as CREB-binding protein (CBP) and p300 (Chrivia
et al., 1993; Gonzalez and Montminy, 1989; Kwok et al., 1994).
Glucagon also causes dephosphorylation of CREB-regulated
transcription coactivator 2 (CRTC2), which translocates into
the nucleus, where it binds and activates CREB (Bittinger
et al., 2004; Koo et al., 2005; Screaton et al., 2004). Among the
genes induced by CREB during fasting is peroxisome prolifera-
tor-activated receptor g coactivator protein-1a (PGC-1a) (Herzigell Metabolism 13, 729–738, June 8, 2011 ª2011 Elsevier Inc. 729
Cell Metabolism
FGF15/19 Regulates Postprandial Hepatic Metabolismet al., 2001), which encodes a transcriptional coactivator protein
that interacts with various DNA-binding transcription factors to
stimulate the expression of genes involved in gluconeogenesis,
fatty acid oxidation, tricarboxylic acid (TCA) cycle flux, and mito-
chondrial oxidative phosphorylation (Burgess et al., 2006; Finck
and Kelly, 2006; Handschin and Spiegelman, 2006; Puigserver
and Spiegelman, 2003). Overexpression of PGC-1a in CREB-
deficient mice restores gluconeogenic gene expression and
glucose homeostasis (Herzig et al., 2001).
In this report, we investigated the effects of FGF15/19 on
hepatic metabolism. We show that FGF15/19 inhibits gluconeo-
genesis through a mechanism involving the dephosphorylation
and inactivationofCREBandsuppressionofPGC-1aexpression.
RESULTS
FGF15/19 Represses PGC-1a and Its Target Genes
in Liver
To characterize the in vivo actions of FGF15/19, we performed
gene expression profiling using liver from fasted wild-type mice
treated with vehicle, FGF15, or FGF19 for 6 hr. As expected for
orthologous proteins, FGF15 and FGF19 showed a strong over-
lap (R2 = 0.73) in the genes that they regulate (Figure S1A). As
expected, FGF15 and FGF19 both suppressed mRNA expres-
sion of the bile acid synthesizing enzyme, Cyp7a1 (Figure 1A)
(Holt et al., 2003; Inagaki et al., 2005). Interestingly, one of the
most strongly downregulated genes in FGF15/19-treated livers
was Pgc1a (Figure 1A). There were corresponding decreases
in PGC-1a protein (Figure 1B) and the PGC-1a target genes
glucose-6-phosphatase (G6Pase), phosphoenolpyruvate car-
boxykinase (Pepck), b subunit of ATP synthase (Atp5b), cyto-
chrome c (Cytc), and isocitrate dehydrogenase (Idh3a), which
encode proteins involved in gluconeogenesis, mitochondrial
oxidative phosphorylation, and TCA cycle flux (Figure 1A).
Peroxisome proliferator-activated receptor-g coactivator-1b
(Pgc1b) was also downregulated by FGF15/19 (Figure 1A) as
reported (Bhatnagar et al., 2009). These results demonstrate
that FGF15/19 regulates the expression of genes involved in
gluconeogenesis and fatty acid oxidation. FGF15/19 did not alter
expression of fatty acid synthase, steroyl CoA desaturase 1, and
acetyl-CoA carboxylase, suggesting that lipogenesis was unaf-
fected (Figure S1B).
To determine the kinetics with which FGF19 regulates gene
expression, wild-type mice were fasted overnight to induce
gluconeogenesis, administered FGF19, and then sacrificed
over a 6 hr time course. Cyp7a1 mRNA levels were reduced
within 4 hr of FGF19 treatment (Figure 1C). Likewise, Pgc1a,
Pepck, and G6pase mRNAs were significantly reduced at the 4
and 6 hr time points (Figure 1C).
We next examined the relative timing of FGF15 and insulin
action following a fasting-refeeding regimen. Wild-type mice
were fasted for 24 hr and then gavaged with a high-carbohy-
drate/high-fat liquid diet. Plasma insulin (Figure 1D) and glucose
levels (Figure 1E) peaked sharply within 15 min after refeeding,
as did liver levels of phosphorylated Akt (Figure 1F), a measure
of insulin action. For technical reasons we are unable to directly
measure circulating FGF15 concentrations. As surrogates,
we measured Fgf15 mRNA in ileum and phosphorylation of
ERK1/2 in liver, which is stimulated by FGF15/19 (Kurosu et al.,730 Cell Metabolism 13, 729–738, June 8, 2011 ª2011 Elsevier Inc.2007). Fgf15mRNA levels increased gradually in the ileum, peak-
ing around 1 hr postgavage (Figure 1D). ERK1/2 phosphorylation
in liver showed a very similar profile (Figure 1F). These data indi-
cate that postprandial FGF15 levels and signaling activity peak
after those of insulin and are consistent with serum FGF19
concentrations in humans peaking 2–3 hr following a meal, well
after insulin levels decrease (Lunda˚sen et al., 2006; Walters
et al., 2009). Plasma glucagon concentrations decreased only
modestly after refeeding (Figure 1E), which is not surprising given
that glucagon levels are already low following a 24 hr fast
(Ahre´n and Havel, 1999; Parker et al., 2002). CREB phosphoryla-
tion was reduced within 15 min of refeeding, remained relatively
low at the 30 and 60 min time points, and then increased
(Figure 1F), suggesting that insulin and FGF15 suppress CREB
activity (see below).
We next used loss-of-function and gain-of-function studies to
determine whether PGC-1a is required for FGF15/19-mediated
repression of gluconeogenic gene expression. For loss-of-func-
tion studies, floxed PGC-1a mice (PGC-1afl/fl) (Lin et al., 2004)
were administered either control adenovirus (Ad-Con) or a Cre
recombinase-expressing adenovirus (Ad-Cre) to eliminate
PGC-1a in liver. Groups of PGC-1afl/fl;Ad-Con and PGC-1afl/fl;
Ad-Cre mice were subsequently fasted and administered either
vehicle or FGF19. PGC-1afl/fl;Ad-Cre mice had the expected
reduction in Pgc1a mRNA in liver and also had reduced basal
expression of G6Pase and Pepck (Figure 2A). As expected,
FGF19 repressed expression of Pgc1a, G6pase, Pepck, and
Cyp7a1 in PGC-1afl/fl;Ad-Con mice. However, the repressive
effect of FGF19 on G6pase and Pepck was lost in PGC-1afl/fl;
Ad-Cre mice (Figure 2A). In contrast, FGF19-mediated repres-
sion of Cyp7a1 occurred in PGC-1afl/fl;Ad-Cre mice, although
basal Cyp7a1 mRNA levels increased in the absence of PGC-
1a (Figure 2A). Thus, FGF19-mediated repression of PGC-1a is
important for the regulation of genes involved in carbohydrate
metabolism but not bile acid metabolism.
In complementary gain-of-function studies, wild-type mice
were infected with either Ad-Con or a PGC-1a-expressing
adenovirus (Ad-PGC-1a). Ad-PGC-1a caused a 15- to 20-fold
increase in hepatic Pgc1a mRNA but did not further increase
basal G6pase and Pepck expression under these fasted con-
ditions (Figure 2B). Subgroups of thesemice were either infected
with an FGF15-expressing adenovirus (Ad-FGF15) or adminis-
tered FGF19. As expected, FGF15 and FGF19 repressed
Pgc1a, G6pase, and Pepck in Ad-Con mice (Figure 2B).
However, under conditions of PGC-1a overexpression, neither
FGF15 nor FGF19 repressed G6pase or Pepck (Figure 2B).
Taken together, the loss-of-function and gain-of-function data
demonstrate that the effects of FGF15/19 on metabolic gene
expression are mediated via regulation of PGC-1a.
The orphan nuclear receptor, small heterodimer partner (SHP),
is required for FGF15/19-mediated repression of Cyp7a1
(Inagaki et al., 2005). To determine whether SHP contributes to
FGF19-mediated repression of gluconeogenic gene expression,
wild-type and SHP-KO mice were administered vehicle or
FGF19, and hepatic gene expression was measured. Unlike
Cyp7a1, repression of Pgc1a, G6pase, and Pepck expression
was maintained in both wild-type and SHP-KO mice (Figure 2C).
Thus, FGF19-mediated repression of gluconeogenic genes does
not require SHP.
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Figure 1. FGF15/19 Represses PGC-1a and Gluconeogenic Gene Expression
(A) Hepatic gene expression measured by quantitative PCR in mice treated with vehicle, FGF15, or FGF19 for 6 hr (n = 4/group). Mice were fasted during the
treatment period.
(B) Western blot analysis of PGC-1a in liver homogenates pooled from groups of four mice treated with vehicle, FGF15, or FGF19 as in (A).
(C) Hepatic gene expression measured by quantitative PCR in overnight-fasted mice injected with FGF19 for the indicated times (n = 4/group).
(D) Ileum Fgf15 mRNA and plasma insulin levels from fasted-refed mice at the indicated times after refeeding (n = 5/group).
(E) Plasma glucose and glucagon levels from fasted-refed mice at the indicated times after refeeding (n = 5/group).
(F) Quantification of hepatic phospho-Akt/total Akt, phospho-ERK1/2/total ERK1/2, and phospho-CREB/total CREB from fasted-refed mice at the indicated
times after refeeding (n = 4/group). Data are shown as percent of maximal phosphorylation for each protein and represent the mean ± SEM. Different lowercase
letters indicate statistical significance (a, p < 0.05; b, p < 0.01; c, p < 0.005; and d, p < 0.001 versus control). See also Figure S1.
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To determine whether the FGF15/19-mediated changes in
hepatic gene expression are accompanied by corresponding
changes in metabolism, metabolic flux was measured by
2H/13C-nuclear magnetic resonance (NMR) isotopomer analysisCin perfused livers isolated from mice infected with either FGF15-
expressing or control adenoviruses. As expected, Pgc1a,
G6pase, Pepck, Atp5b, Cytc, Idh3a, and Cyp7a1 were signifi-
cantly reduced in liver from mice administered Ad-FGF15
(Figure 3A). Consistent with these gene expression data, hepaticell Metabolism 13, 729–738, June 8, 2011 ª2011 Elsevier Inc. 731
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Figure 2. PGC-1a, but Not SHP, Is Required for FGF15/19 Regulation
of Metabolic Gene Expression
(A) Hepatic gene expression analyzed by quantitative PCR in groups of
PGC-1afl/fl mice administered control (Ad-Con) or Cre-expressing (Ad-Cre)
adenovirus and subsequently administered vehicle or FGF19 for 6 hr (n = 5–6/
group). Mice were fasted during the treatment period.
(B) Hepatic gene expression analyzed by quantitative PCR in groups of wild-
type (WT) mice infected with Ad-Con or PGC-1a-expressing adenovirus
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732 Cell Metabolism 13, 729–738, June 8, 2011 ª2011 Elsevier Inc.gluconeogenesis, TCA cycle flux, and b-oxidation were signifi-
cantly reduced, and ketogenesis trended lower in liver exposed
to FGF15 (Figure 3B). In experiments performed in parallel,
adenoviral expression of FGF15 significantly decreased plasma
glucose concentrations and caused downward trends in insulin
and ketone body levels, but did not affect plasma glucagon
concentrations (Figure 3C). In complementary experiments,
more acute administration of recombinant FGF19 did not signif-
icantly alter plasma glucagon or insulin levels (Figures S2A and
S2B). Consistent with decreased Cyp7a1 expression, hepatic
cholesterol levels were significantly increased in mice infected
with the FGF15-expressing adenovirus (Figure 3C). Both plasma
and hepatic triglyceride concentrations trended lower in
response to FGF15 (Figures S2C and S2D), which is surprising
in light of the effect FGF15 has on hepatic b-oxidation. In related
experiments, acute FGF19 administration had no effect on
hepatic triglyceride concentrations (Figure S2E), and FGF15-
KO mice showed no change in hepatic triglyceride concentra-
tions compared to wild-type mice (Figure S2F). These paradox-
ical results may be the consequence of FGF15/19 also acting on
tissues other than liver. Taken together, these NMR isotopomer
and metabolic parameter data demonstrate that FGF15/19
suppresses several hepatic metabolic pathways, including
gluconeogenesis, TCA cycle flux, and fatty acid oxidation, which
are induced during fasting.
To determine whether FGF15/19-mediated repression of glu-
coneogenic gene expression might be an indirect consequence
of increased insulin sensitivity, insulin tolerance tests (ITTs) were
performed in mice administered either vehicle or FGF19 or in
mice administered control or FGF15-expressing adenovirus. In
both experiments, mice treated with FGF19 or FGF15 exhibited
similar insulin sensitivity compared to their respective controls
(Figures S2G and S2H). To further test whether FGF19 improves
hepatic insulin sensitivity, hyperinsulinemic/euglycemic clamps
were performed. Consistent with the ITT results, mice adminis-
tered FGF19 demonstrated sensitivity to insulin equivalent to
that of vehicle-treated animals (Figures S2I and S2J). Thus,
FGF15/19 does not improve insulin sensitivity in lean mice.
FGF15-KO and FGFR4-KO mice were used to directly assess
the physiologic relevance of the FGF15/19-FGFR4 pathway
in regulating gluconeogenesis. Pgc1a, Pepck, and G6pase
mRNA levels were significantly elevated in liver from fed
FGF15-KO and FGFR4-KO mice (Figures 3D and 3E). To deter-
mine whether these changes in gene expression corresponded
with increased gluconeogenesis, we performed a modified
pyruvate/lactate challenge using uniformly labeled [13C]pyruvate
and lactate in fed wild-type and FGF15-KO mice. Intraperitoneal
(i.p.) administration of pyruvate/lactate caused a significantly
greater increase in plasma glucose levels in FGF15-KO mice(Ad-PGC-1a) and subsequently administered vehicle or FGF19 for 6 hr. Mice
were fasted during the treatment period. Subgroups of the Ad-Con and
Ad-PGC-1a groups were coadministered an FGF15-expressing adenovirus
(Ad-FGF15). All mice were fasted during the last 6 hr of the experiment
(n = 5–7/group).
(C) Hepatic gene expression analyzed by quantitative PCR in groups ofWT and
SHP-KO mice administered vehicle or FGF19 for 6 hr (n = 4/group). Mice
were fasted during the treatment period. Data are presented as mean ± SEM
(a, p < 0.05; b, p < 0.01; c, p < 0.005; d, p < 0.001).
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analysis verified that the additional plasma glucose was derived
from labeled substrate (Figure 3G). Taken together, these data
demonstrate that FGF15 contributes to the repression of gluco-
neogenesis in the fed state.
To further examine the physiological consequences of FGF15
and FGFR4 deficiency, FGF15-KO and FGFR4-KO mice and
their wild-type counterparts were fasted 24 hr and fed a high-
carbohydrate/high-fat liquid diet by oral gavage, and their blood
glucose levels were analyzed over time. Blood glucose levels
were elevated significantly in the FGF15-KO mice at the 1 and
2 hr time points (Figure 3H) and in the FGFR4-KO mice at the
2 hr time point (Figure 3I), indicating an impaired postprandial
response when the FGF15-FGFR4 pathway is disrupted. Plasma
insulin levels were not significantly altered in either FGF15-KO or
FGFR4-KO mice, although there was a trend toward decreased
plasma insulin concentrations in the FGFR4-KOmice (Figures 3J
and 3K). ITT in FGF15-KO and FGFR4-KO mice revealed no
changes in insulin sensitivity (Figures S2K and S2L). In addition,
plasma glucagon levels did not differ between wild-type and
FGF15-KOmice (Figure S2M). Thus, the FGF15-FGFR4 pathway
modulates postprandial carbohydrate homeostasis without
affecting insulin sensitivity or glucagon concentrations.
FGF15/19 Represses CREB
To gain insight into how FGF15/19 represses Pgc1a, we
analyzed candidate signaling pathways for activation by FGF19
in vivo. Fasted wild-type and FGFR4-KO mice were adminis-
tered FGF19 or vehicle for 30 min, and multiple phosphorylation
cascades were analyzed. As expected, administration of FGF19
increased FRS2a and ERK1/2 phosphorylation in liver of wild-
type but not FGFR4-KO mice (Figure 4A). FGF19 had no effect
on the phosphorylation of either Akt or FOXO1. However,
FGF19 caused a marked reduction in the phosphorylation of
CREB at Ser133, a site that regulates CREB transcriptional
activity (Gonzalez and Montminy, 1989), in wild-type but not
FGFR4-KO mice (Figure 4A).
Since CREB induces Pgc1a by binding to a cAMP response
element (CRE) in the Pgc1a promoter and recruiting coactivator
proteins such as CBP (Herzig et al., 2001), we performed chro-
matin immunoprecipitation (ChIP) analysis for CREB and CBP
using liver from mice treated with vehicle or FGF19. Administra-
tion of FGF19 reduced CREB and CBP binding to the Pgc1a
promoter (Figure 4B). CREB and CBP binding were also reduced
in liver frommice infected with an FGF15-expressing adenovirus
(Figure 4C). These data indicate that FGF15/19 inhibits Pgc1a
expression by reducing the phosphorylation and transcriptional
activity of CREB. Additional ChIP analyses of the G6Pase and
Pepck promoters revealed that FGF15 also reduced PGC-1a
binding to these promoters (Figures 4D and 4E). Interestingly,
FGF15 decreased CREB binding to the G6Pase promoter, but
not the Pepck promoter (Figures 4D and 4E). The basis for this
difference is not known.
To confirm the effect of FGF15/19 on hepatic CREB activity,
wild-type mice were infected with an adenovirus containing
a CRE-luciferase (luc) reporter (Ad-CRE-luc) and then adminis-
tered either vehicle or FGF19. As expected, Ad-CRE-luc-
infected mice treated with vehicle showed significant induction
of luciferase activity in response to a 6 hr fast (Figure 4F). ThisCinduction of luciferase activity was markedly attenuated in
mice treated with FGF19 (Figures 4F and 4G). Thus, FGF19 effi-
ciently suppresses hepatic CREB activity in vivo.
DISCUSSION
We recently showed that FGF15/19 stimulates glycogen and
protein synthesis in liver (Kir et al., 2011). We now show that
FGF15/19 represses hepatic gluconeogenesis, TCA cycle flux,
and fatty acid oxidation. While there is striking overlap in the
actions of FGF15/19 and insulin on liver, there are important
temporal and mechanistic differences. Insulin is released rapidly
from the pancreas following a meal. In our fasting-refeeding
experiments, serum insulin concentrations and downstream
Akt phosphorylation in liver peaked approximately 15 min after
gavage with a high-carbohydrate/high-fat liquid diet. While we
were unable to directly measure circulating FGF15 concentra-
tions, Fgf15 mRNA levels in ileum and downstream ERK1/2
phosphorylation in liver peaked approximately 1 hr postgavage.
Thus, we propose that FGF15 acts subsequent to insulin.
Consistent with this hypothesis, serum FGF19 levels increase
in humans 2–3 hr following a meal, when bile acid flux increases
across the ileum (Lunda˚sen et al., 2006; Walters et al., 2009). We
suggest that FGF15/19 provides a mechanism for regulating
metabolism in liver after circulating insulin concentrations have
dissipated, thereby easing the transition from the fed to the
fasted state. The physiologic importance of this pathway is
underscored by FGF15-KO and FGFR4-KO mice, which have
increased gluconeogenic gene expression under fed conditions
and hyperglycemia in response to fasting-refeeding challenge.
Moreover, FGF15-KO mice have elevated glucose levels in
response to pyruvate/lactate challenge. Interestingly, circulating
FGF19 concentrations were recently shown to be negatively
correlated with fasting glucose levels and metabolic syndrome
in humans (Reiche et al., 2010; Stejskal et al., 2008). Our meta-
bolic flux measurements indicate that FGF15/19 likely contrib-
utes to glycemic control in part by suppressing hepatic
gluconeogenesis.
We show that FGF15/19 suppresses gluconeogenic gene
expression through a pathway distinct from that of insulin. Phos-
phorylation of CREB at Ser133, which occurs during fasting,
causes it to associate with the coactivators p300 and CBP and
to induce gluconeogenic gene expression (Chrivia et al., 1993;
Gonzalez and Montminy, 1989; Kwok et al., 1994). FGF15/19
has the opposite effect, inhibiting CREB phosphorylation and
its recruitment to the Pgc1a and G6Pase promoters. These
data suggest that the effects of FGF15/19 on liver are likely to
extend to other processes regulated by CREB. Since FGF19
treatment caused a trend toward reduced hepatic CRTC2
concentrations (Figure S3A), we cannot exclude that this also
contributes to FGF15/19-mediated regulation of CREB activity.
It is presently unclear how FGF15/19 signaling causes CREB
dephosphorylation. Given that phosphorylation of CREB at
Ser133 has a half-life of 30 min in NIH 3T3 cells (Michael
et al., 2000), the rapidity with which CREB is dephosphorylated
in liver suggests that FGF15/19 might activate phosphatases.
Several CREB phosphatases, including PP1 and PP2A, have
been described (Hagiwara et al., 1992; Wadzinski et al., 1993).
However, we have not seen changes in PP1 and PP2A activityell Metabolism 13, 729–738, June 8, 2011 ª2011 Elsevier Inc. 733
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Figure 4. FGF15/19 Signaling Reduces CREB Phosphorylation and Activity
(A) Western blot analysis of total and phosphorylated FRS2a, ERK1/2, CREB, Akt, and FOXO1 in liver lysates from individual overnight-fasted wild-type (WT) and
FGFR4-knockout (KO) mice 30 min after treatment with vehicle or FGF19. b-actin served as a loading control.
(B–E) ChIP analysis of the cyclic AMP response elements (CRE) in the Pgc1a, G6pase, and Pepck promoters using CREB, CBP, and PGC-1a antibodies as
indicated and pooled liver lysates (three repeats/pool; n = 4/pool of each group). For (B), mice were administered saline or FGF19 for 1 hr and fasted during the
treatment period. For (C)–(E), mice were injected with control or FGF15-expressing adenovirus for 3 days and killed after an overnight fast.
(F) Images of luciferase activity in mice infected with a CRE-luciferase reporter (Ad-CRE-luc) or control adenovirus and subsequently treated with vehicle or
FGF19 for 6 hr. Mice were fasted during the treatment period.
(G) Quantified luciferase activity normalized to the number of virus particles per liver (n = 6/group). All data are presented as mean ± SEM (c, p < 0.005). See also
Figure S3.
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ure S3B). A previous study showed that pharmacologic activa-
tion of ERK1/2 with an inhibitor of protein phosphatase,Figure 3. FGF15 Represses Hepatic Gluconeogenesis, TCA Cycle Flux
(A) Hepatic gene expression measured by quantitative PCR in mice infected with
fasted overnight (n = 5/group).
(B)Metabolic pathway fluxmeasured byNMR in perfused livers frommice infected
(C) Metabolic parameters in mice infected with control (Con) or FGF15-expressin
(D and E) Hepatic gene expression measured by quantitative PCR in fed FGF15-
(n = 6/group).
(F andG) Plasma glucose (F) andmole percent (%) labeled glucose versus unlabel
KO mice (n = 5–6/group).
(H–K) Plasma glucose and insulin concentrations in fasted-refed WT, FGF15-KO,
are presented as mean ± SEM (a, p < 0.05; b, p < 0.01; c, p < 0.005; d, p < 0.00
CCdc25A, causes rapid CREB dephosphorylation in hepatoma
cells through a mechanism involving inhibition of ribosomal S6
kinase (Wang et al., 2003). Although FGF15/19 efficiently, and Fatty Acid Oxidation
control (Con) or FGF15-expressing adenovirus (Ad-FGF15) for 3 days and then
with control or FGF15-expressing adenovirus and fasted as in (A) (n = 8/group).
g adenovirus (Ad-FGF15) for 3 days and then fasted for 6 hr (n = 8/group).
knockout (KO) (D) or FGFR4-KO mice (E) or their wild-type (WT) counterparts
ed glucose (G) following a labeled pyruvate/lactate challenge inWT and FGF15-
and FGFR4-KO mice at the indicated times after refeeding (n = 6/group). Data
1). See also Figure S2.
ell Metabolism 13, 729–738, June 8, 2011 ª2011 Elsevier Inc. 735
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(Kir et al., 2011), indicating that this pathway is unlikely to be rele-
vant to FGF15/19-mediated inhibition of CREB phosphorylation.
We also did not detect changes in PKA activity by western blot
analysis using a phosphorylated PKA substrate antibody and
liver extracts from FGF19-treated mice (Figure S3C). Thus, addi-
tional studies will be required to determine how FGF15/19
affects CREB phosphorylation.
Our finding that FGF15/19 represses fatty acid oxidation in
isolated liver is surprising in light of our data showing that neither
FGF15 nor FGF19 significantly affected hepatic triglyceride
levels and previous studies showing that whole-body fatty
acid oxidation and hepatic triglyceride concentrations are
decreased by either pharmacologic administration of recombi-
nant FGF19 or its transgenic overexpression (Fu et al., 2004;
Tomlinson et al., 2002). A similar paradox was reported in
mice lacking FGFR4, the receptor for FGF15/19 in liver: whereas
global FGFR4-KO mice had increased white adipose tissue
mass, they were resistant to diet-induced fatty liver, suggesting
that FGFR4 represses hepatic fatty acid catabolism (Huang
et al., 2007). These data suggest that the net metabolic profile
of FGF15/19 involves effects on additional tissues. In this re-
gard, FGF19-transgenic mice have increased brown adipose
tissue mass and thermogenesis (Tomlinson et al., 2002), and
injection of recombinant FGF19 into mice activates the
FRS2a/ERK1/2 pathway in white adipose tissue (Kurosu et al.,
2007). Moreover, intracerebroventricular injection of FGF19
increases metabolic rate (Fu et al., 2004), indicating that
FGF19 can act on the central nervous system to mediate
some of its effects. The relative contribution of liver versus other
tissues to the physiologic and pharmacologic effects of FGF15/
19 remains to be determined.
In summary, we show that FGF15/19 inhibits hepatic gluco-
neogenesis through a pathway involving inhibition of the
CREB-PGC-1a signaling cascade. We conclude that FGF15/
19 is a late postprandial signal in the temporal cascade of
hormones that control hepatic metabolism in response to nutri-
tional status.
EXPERIMENTAL PROCEDURES
Animal Experiments
FGF15-KO, FGFR4-KO, SHP-KO, and PGC-1afl/fl mice were as described
(Inagaki et al., 2005; Kerr et al., 2002; Lin et al., 2004; Wright et al., 2004; Yu
et al., 2000). Mice were fed standard chow containing 4% fat (Harlan Teklad,
#2016). For fasting-refeeding experiments, wild-type, FGF15-KO, and
FGFR4-KO mice were fasted 24 hr and subjected to a bolus (20 ml/g body
weight) of a nutrient-rich diet (Ensure, Abbott Laboratories) by oral gavage.
Aliquots of tail blood were withdrawn for analysis of glucose, insulin and
glucagon levels. Six hour fasting experiments were performed from 6 p.m. to
12 a.m. unless otherwise specified, and 24 hr fasting experiments were per-
formed from 9 a.m. to 9 a.m. ITTs were performed by i.p. injection of 0.75 U
insulin/kg body weight into mice following a 4–6 hr fast. All animal experiments
were approved by the Institutional Animal Care and Research Advisory
Committee of the University of Texas Southwestern Medical Center.
FGF Injection Experiments
FGF15 and FGF19 were expressed in 911 cells and E. coli, respectively, and
purified as described (Choi et al., 2006; Inagaki et al., 2005). For the microarray
studies, FGF15 and FGF19were injected intomice intravenously at concentra-
tions of 0.15 mg/g body weight and 1 mg/g body weight, respectively. For all
other studies, FGF19 was injected i.p. at 1 mg/g.736 Cell Metabolism 13, 729–738, June 8, 2011 ª2011 Elsevier Inc.Adenovirus Infections
Control, FGF15, PGC-1a, and Cre-recombinase adenovirus injections were
performed as described (Inagaki et al., 2005; Lehman et al., 2000). Briefly,
7.5 3 109 particles/g body weight of adenovirus was delivered intravenously
by jugular vein injection into 10- to 14-week-old C57BL/6 males (Jackson
Laboratory) for FGF15 and PGC-1a overexpression studies or 12- to
14-week-old PGC-1afl/fl mice for the Cre-recombinase experiment. Three
days after infection of the control, FGF15, PGC-1a adenoviruses, or combina-
tion thereof, mice were administered FGF19 or vehicle and fasted for the indi-
cated time. Livers were subsequently isolated and perfused for NMR tracer
studies or used for mRNA analysis. For acute, hepatic deletion of PGC-1a,
Cre-expressing adenovirus or control adenovirus was administered to PGC-
1afl/fl mice, followed by 9 days of recovery. Mice were then administered
vehicle or FGF19 and fasted for the indicated time, and livers were subse-
quently isolated for mRNA analysis.
Ad-CRE-luc activity wasmeasured as described (Dentin et al., 2007). Briefly,
7.5 3 109 particles/g body weight of an adenovirus expressing a cyclic AMP
response element (CRE) driving luciferase (Ad-CRE-luc; a gift from Marc
Montminy, Salk Institute) was injected by jugular vein into wild-type 12- to
16-week-old C57BL/6 males. Three days after infection, mice were adminis-
tered vehicle or FGF19 and then fasted for 6 hr (6 p.m. to 12 a.m.). In vivo
luciferase activity was measured using an IVIS lumina imaging system
following luciferin injection, and luciferase activity (photons/s) was normalized
to copies of virus DNA infected per liver determined by quantitative PCR
analysis of hexon gene expression (Hogg et al., 2010).
In Vivo and Ex Vivo Tracer Studies
Livers from overnight-fasted control and FGF15-expressing adenovirus-
infected wild-type mice were isolated and perfused for 60 min in a nonrecircu-
lating fashion at 8 ml/min with a Krebs-Henseleit-based perfusion medium as
described (Burgess et al., 2003). Ketone and glucose production were deter-
mined by standard biochemical assays of the effluent perfusate. Oxygen
consumption was determined by oxygen electrode. Relative gluconeogenesis
and glycogenolysis were determined using the deuterated water method with
deuterium enrichment detected in effluent perfusate glucose by 2H-NMR.
Relative fluxes through PC/PEPCK and the TCA cycle were determined by
[13C]isotopomer analysis of effluent perfusate glucose. Relative fluxes were
multiplied by absolute hepatic glucose production to determine absolute flux
through these pathways.
Pyruvate/lactate challenge experiments were performed by i.p. injection of
uniformly labeled pyruvate (1 g/kg mouse; [U-13C3] pyruvate [sodium salt],
Cambridge Isotope Laboratories, Inc.) and uniformly labeled sodium lactate
(2 g/kg mouse; [U-13C3]lactate [sodium salt], Cambridge Isotope Laboratories,
Inc.) into ad libitum-fed wild-type and FGF15-KO mice at 8 p.m. (normal light/
dark cycle 6 a.m.-6 p.m.). Pyruvate and lactate were provided together tomini-
mize perturbations of redox state. Twenty minutes prior to treatment, food was
removed for the duration of the experiment. Approximately 30 ml of tail blood
was then collected at the indicated times, and plasma glucose was analyzed.
Remaining blood was used to measure glucose enrichments by GC-MS as
described (Sunny and Bequette, 2010). M+3 was monitored and indicated
conversion of pyruvate/lactate to glucose.
Jugular catheters were surgically implanted and the mice were allowed to
recover for 5 days. FGF19 was administered by i.p. injection. Twenty minutes
after administration of FGF19, basal endogenous glucose production was
determined by steady-state infusion of [U-13C]glucose for 90 min, after which
blood samples (50 ml) were collected from the tail vein for isotope dilution
analysis of blood glucose by mass spectrometry. At 90 min, a hyperinsuline-
mic-euglycemic clamp was initiated after restraining the mice in a tube holder
as described (Ayala et al., 2006, 2010; DeFronzo et al., 1979; Kraegen et al.,
1983). Mice were acclimated to the tube holder by daily exposure for
6–8 days prior to the clamp. Briefly, insulin was infused at a constant rate
(5 mU/kg/min) together with a variable infusion of 30% glucose solution
enriched to 2.5% with [U-13C]glucose to maintain euglycemia. Blood glucose
levels were monitored from the tail vein every 10 min using a glucometer, and
necessary adjustments to the glucose infusion rate were made to maintain eu-
glycemia. Following 70–80 min of hyperinsulinemic euglycemia to achieve
steady-state glucose enrichments in the blood, the mice were sacrificed,
and blood/tissue samples were collected and stored at 80C until analysis.
Cell Metabolism
FGF15/19 Regulates Postprandial Hepatic MetabolismGlucose enrichments were determined by GC-MS as described (Sunny and
Bequette, 2010).
Statistical Analyses
Statistical analyseswere performed as described (Burgess et al., 2007; Inagaki
et al., 2007).
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